Today, Cynata's CEO and MD, Dr Kilian Kelly and CBO Dr Mathias Kroll, provided an update to investors, following the release of the Phase 1 diabetic foot ulcer clinical trial results.

Euroz Hartleys analyst Seth Lizee has initiated research coverage on Cynata. Read the report here.

Watch the presentation by Dr Kilian Kelly, Cynata's CEO and MD, at the Alliance for Regenerative Medicine Meeting on the Mesa, in Phoenix, Arizona.

Read the latest coverage of Cynata by renowned small-cap share analyst and business journalist Tim Boreham, as featured in Biotech Daily, Stockhead and The Australian.

Today, Cynata's CEO and MD, Dr Kilian Kelly, alongside CBO Dr Mathias Kroll and Chair Dr Geoff Brooke, provided an update to investors, following the release of the FY 2024 Annual Report.